Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Trevi Therapeutics, Inc. (TRVI)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.2200-0.0500 (-2.20%)
At close: 04:00PM EDT
2.2400 +0.02 (+0.90%)
After hours: 04:42PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.2700
Open2.2400
Bid2.0800 x 800
Ask2.2400 x 1000
Day's Range2.1600 - 2.3400
52 Week Range0.4600 - 3.7310
Volume205,935
Avg. Volume720,882
Market Cap57.379M
Beta (5Y Monthly)0.59
PE Ratio (TTM)N/A
EPS (TTM)-1.7560
Earnings DateMar 23, 2022 - Mar 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.67
  • TipRanks

    These 2 Penny Stocks Have Over 300% Upside on the Horizon, Says Oppenheimer

    Earlier this month, the S&P 500 officially entered a bear market; its current year-to-date loss stands at 21%, and the NASDAQ, which has fallen faster and farther, stands at a 30% ytd loss. The rapid reversal not only put the bulls back in the corral, but also erased all of last year’s stock market gains, leading most analysts to start meditating on the prospects of recession. Among the headwinds they’re considering are the highest rates of inflation in over 40 years and in response, a sharp tur

  • PR Newswire

    Trevi Therapeutics to Present and Participate in Partnership Meetings at Upcoming 2022 BIO International Convention

    Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER) for pruritus in prurigo nodularis (PN) and chronic cough in idiopathic pulmonary fibrosis (IPF), today announced that Jennifer Good, President and CEO, will deliver a company presentation at 2022 BIO International Convention. In addition, Ms. Good will be participating in partnership meetings throughout the conference alongside Farrell Simon, SVP, Hea

  • PR Newswire

    Trevi Therapeutics Announces First Quarter 2022 Financial Results and Business Update

    Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER) for pruritus in prurigo nodularis (PN) and chronic cough in idiopathic pulmonary fibrosis (IPF), today announced financial results for the quarter ended March 31, 2022, as well as provided business updates.

Advertisement
Advertisement